-
The 6th Coloplast WOCF Enterostomy Nursing Sub-Forum focuses on new developments in the field of enterostomy
Time of Update: 2022-05-23
Li Houmin, chief physician of the Department of Dermatology, Peking University People's Hospital, said: The early prevention of skin problems around the stoma can reduce the physical and psychological burden of the stoma patient, thereby improving the quality of life of the stoma patient .
-
Cell and gene therapy represented by CAR-T therapy has become a prairie prairie
Time of Update: 2022-05-23
? Standardized development stage (2016-present) In 2017, the State Food and Drug Administration promulgated the "Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial)", which proposed the safety, Valid, quality-controllable general technical requirements .
-
50+ anti-PD drugs have been approved for marketing; multi-enterprise joint deployment, Nuggets innovative therapies, AbbVie, Biogen...
Time of Update: 2022-05-22
Published results of a Phase 1b clinical trial of the drug in PD showed that of 15 patients with advanced PD who received a single gene therapy treatment, 14 patients still experienced improvement in disease grade after 3 years of treatment .
-
Sri Lanka Microorganism Announces Collaboration with Baidu Research Institute to Accelerate mRNA Vaccine and Drug Development with AI Empowerment
Time of Update: 2022-05-22
In addition to expanding the optimization of linear mRNA algorithm research, the two parties will try to develop circular RNA and other sequence design iteration technologies.
-
JAK inhibitors are accelerating in China!
Time of Update: 2022-05-22
On April 11, the official website of the China National Medical Products Administration (NMPA) announced that Pfizer's oral JAK1 inhibitor abrocitinib (abrocitinib, Chinese brand name Cipike) was approved for marketing in China, suitable for This is also the second JAK inhibitor approved by Pfizer in China for adult patients with refractory, moderate-to-severe atopic dermatitis who do not respond well to other systemic treatments (such as hormones or biological agents) or who are not suitable for the above treatments .
-
What core trials are included in the Phase I clinical phase of innovative drugs?
Time of Update: 2022-05-21
Its purpose is to understand the dose response and toxicity; to carry out preliminary safety evaluation, to study the human body's tolerance and pharmacokinetics of new drugs, and to provide a preliminary dosing scheme; the subjects are generally healthy volunteers, and in special cases Patients were also selected as subjects under certain circumstances; the methods were open, controlled, randomized, and blinded; the number of subjects was 20-30 .
-
AbbVie Announces Phase 2 Clinical Data of navitoclax in Myelofibrosis 2022 AACR
Time of Update: 2022-05-21
Recently, AbbVie presented new data from the Phase 2 REFINE (NCT03222609) trial of navitoclax in combination with ruxolitinib (a JAK1/2 inhibitor) in myelofibrosis (MF) at the 2022 American Association for Cancer Research (AACR) annual meeting .
-
Anlotinib's fifth indication - iodine-refractory differentiated thyroid cancer officially approved
Time of Update: 2022-05-21
China's National Medical Products Administration (NMPA) officially approved Chia Tai Tianqing's Class 1 new drug for the treatment of patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) .
-
Everything can be connected!
Time of Update: 2022-05-21
Not long ago, Novartis announced that its targeted radioligand therapy Pluvicto (lutetiumLu177vipivotidetetraxetan, 177Lu-PSMA-617) was approved by the FDA for the treatment of PSMA positive, and after taxane chemotherapy and androgen receptor signaling pathway inhibitors Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) .
-
38 new drugs have been approved for clinical use, and both traditional Chinese medicine and biological drugs have exploded!
Time of Update: 2022-05-21
The clinically approved innovative drugs include peptide tumor vaccines, multiple double antibodies, PROTACs, new Chinese medicines, etc.
The indications that have obtained the default approval for this clinical trial are for the treatment of HER2-positive advanced solid tumors, including HER2-positive breast cancer.
-
The anticancer drug is expected to become the first domestically-made oral drug for the new crown. What is the sacredness of Prokluamide?
Time of Update: 2022-05-21
On April 6, Kintor Pharma announced the key data results of the Phase III global multi-center clinical trial (NCT04870606) of prokalutamide in the treatment of mild to moderate non-hospitalized patients with COVID-19.
-
Accurate assessment of recurrence risk in 15 years: breast cancer polygenic detection
Time of Update: 2022-05-21
The 2021 edition of the Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Specifications (CACA Guidelines) [1] mentioned that it is necessary to comprehensively consider clinical factors and genetic testing results to evaluate the risk of patients (risk of distant recurrence), and make adjuvant treatment decisions .
-
$5 billion large variety was looted Chia Tai Tianqing entered the game
Time of Update: 2022-05-21
Figure 1: The latest products declared by Chia Tai Tianqing Pharmaceutical Group Source: CDE official website It is reported that palbociclib was first developed by Pfizer and is the first CDK4/6 inhibitor to be marketed in the world.
-
Double happiness for Hengrui!
Time of Update: 2022-05-21
Table 1: The ANDA number that Hengrui has obtained Source: Minet Global Listed Drug Database On April 15, Jiangsu Hengrui Pharmaceutical announced that the company's abbreviated new drug application (ANDA) for gadoteric acid meglumine injection submitted to the US FDA was approved, which means that the product can be produced and sold in the US market .
-
Stone medicine exerts force!
Time of Update: 2022-05-21
Recently, CSPC's product line welcomes new progress: esomeprazole sodium for injection, a powerful acid-suppressing drug, will be approved, and the new crown mRNA vaccine will be approved for clinica
-
Burning Rock Medicine: From defense to offense, making cancer prevention and treatment "early"
Time of Update: 2022-05-21
Faced with the current situation that 80% of cancer patients in China are found to be in the middle and late stages, at the beginning of the 28th National Cancer Prevention and Control Awareness Week, Burning Rock calls on everyone to respond to this year's theme "Early Action for Cancer Prevention and Control", from defense to attack, let the Cancer prevention is one step earlier .
-
ACC008 Phase III clinical trial completed the enrolment of clinical subjects
Time of Update: 2022-05-21
At the same time, ACC008 completed the bioequivalence trial in March 2021, and the new drug marketing application for HIV-infected patients was accepted by NMPA in May 2021 and is currently under review .
-
Novartis' canakinumab in NSCLC phase 3 trial failed again 2022 AACR
Time of Update: 2022-05-21
Novartis' latest data from the CANOPY-1 Phase 3 trial presented at the American Association for Cancer Research (AACR) annual meeting show that in patients with newly diagnosed metastatic non-small cell lung cancer, canakinumab monoclonal antibody combined with Merck's Keytruda reduces the risk of death13 %, a 17% lower risk of disease progression or death .
-
The marketing application of Shandong New Era Metformin Hydrochloride Sustained-Release Tablets was approved
Time of Update: 2022-05-20
Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals Source: new version database of Minet Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
-
TauRx Alzheimer's Disease Drug Approved in China Phase III; dMed-Clinipace as Partner
Time of Update: 2022-05-20
KM Seng (Doctor Xin Guangming) was to bring an effective and accessible Alzheimer's disease (AD) treatment to patients around the world, with China's national medicine With the approval of the New Drug Clinical Trial Application (NMPA), we are one step closer to achieving this goal .
